S-benzyl phenylmethanethiosulfinate: an antioxidant; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10244468 |
| CHEMBL ID | 1224167 |
| SCHEMBL ID | 10391146 |
| MeSH ID | M0522614 |
| Synonym |
|---|
| s-benzyl phenylmethanesulfinothioate |
| CHEMBL1224167 , |
| benzenemethanesulfinothioic acid, s-(phenylmethyl) ester |
| benzylsulfinylsulfanylmethylbenzene |
| petivericin |
| s-benzyl phenylmethanethiosulfinate |
| bdbm50325648 |
| 16302-98-0 |
| SCHEMBL10391146 |
| DTXSID90437280 |
| phenylmethanethiosulfinic acid s-benzyl ester |
| SY359041 |
| mfcd00443820 |
| Pathway | Proteins | Compounds |
|---|---|---|
| (Z)-phenylmethanethial S-oxide biosynthesis | 1 | 8 |
| (Z)-phenylmethanethial S-oxide biosynthesis | 0 | 9 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Procathepsin L | Homo sapiens (human) | Ki | 31.7000 | 0.0000 | 1.1013 | 9.3000 | AID502278 |
| Cathepsin B | Homo sapiens (human) | Ki | 7.8000 | 0.0000 | 1.2180 | 8.6000 | AID502276 |
| Cysteine protease | Trypanosoma brucei rhodesiense | Ki | 2.3100 | 0.0350 | 2.5517 | 5.3100 | AID502282 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID502276 | Inhibition of cathepsin B | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502287 | Time dependent inhibition of Trypanosoma brucei rhodesiense rhodesain by Dixon plot analysis | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502278 | Inhibition of cathepsin L | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502284 | Antiparasitic activity against Trypanosoma brucei brucei | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502283 | Antiparasitic activity against Plasmodium falciparum | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502281 | Inhibition of Plasmodium falciparum falcipain-2 | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502286 | Time dependent inhibition of Plasmodium falciparum falcipain-2 by Dixon plot analysis | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| AID502282 | Inhibition of Trypanosoma brucei rhodesiense rhodesain | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||